Floatz logo

288 assets in Lymphoma

Therapeutic assets addressing Lymphoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Nelarabine
Lymphoma
University of ChicagoP2CCC (54)
Nepenthe
Lymphoma
St. Louis UniversityP3CCC (54)
Binimetinib
Lymphoma
National Cancer Institute (NCI)P2CCC (53)
Copanlisib
Lymphoma
National Cancer Institute (NCI)P2CCC (53)
Crizotinib
Lymphoma
National Cancer Institute (NCI)P2CCC (53)
Dabrafenib
Lymphoma
National Cancer Institute (NCI)P2CCC (53)
Defactinib
Lymphoma
National Cancer Institute (NCI)P2CCC (53)
Gsk-2636771
Lymphoma
National Cancer Institute (NCI)P2CCC (53)
Ipatasertib
Lymphoma
National Cancer Institute (NCI)P2CCC (53)
Larotrectinib
Lymphoma
National Cancer Institute (NCI)P2CCC (53)
Osimertinib
Lymphoma
National Cancer Institute (NCI)P2CCC (53)
Palbociclib
Lymphoma
National Cancer Institute (NCI)P2CCC (53)
Pertuzumab
Lymphoma
National Cancer Institute (NCI)P2CCC (53)
Relatlimab
Lymphoma
National Cancer Institute (NCI)P2CCC (53)
Sapanisertib
Lymphoma
National Cancer Institute (NCI)P2CCC (53)
Selpercatinib
Lymphoma
National Cancer Institute (NCI)P2CCC (53)
Teonanacatl
Lymphoma
University Health Network, TorontoP2CCC (53)
Trametinib
Lymphoma
National Cancer Institute (NCI)P2CCC (53)
Trastuzumab
Lymphoma
National Cancer Institute (NCI)P2CCC (53)
Ulixertinib
Lymphoma
National Cancer Institute (NCI)P2CCC (53)
Vismodegib
Lymphoma
National Cancer Institute (NCI)P2CCC (53)
Zamtocabtagene Autoleucel
Lymphoma
Miltenyi Biomedicine GmbHP2CCC (53)
1H-BENZIMIDAZOLE, 2-(((4-(3-METHOXYPROPOXY)-3-METHYL-2-PYRIDINYL)METHYL)SULFINYL)-, SODIUM SALT, HYDRATE (1:1:1)
Lymphoma
HutchmedP1CCC (52)
Adavosertib
Lymphoma
National Cancer Institute (NCI)P2CCC (52)
Axicabtagene Ciloleucel
Lymphoma
The First Affiliated Hospital of Xiamen UniversityP2CCC (52)
cd22 car-transduced t cells
Lymphoma
Liping DouP2CCC (52)
Decitabine
Lymphoma
Mayo ClinicP2CCC (52)
Famotidine
Lymphoma
Sherief Abd-ElsalamP3CCC (52)
Grastofil
Lymphoma
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sP3CCC (52)
hx009
Lymphoma
Hangzhou Hanx Biopharmaceuticals, Ltd.P1/2CCC (52)
Lansoprazole
Lymphoma
Sherief Abd-ElsalamP3CCC (52)
Lapelga
Lymphoma
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sP3CCC (52)
L-Dep
Lymphoma
Beijing Friendship HospitalP3CCC (52)
Oxycodone
Lymphoma
St. Louis UniversityP3CCC (52)
Oxycodone Hydrochloride, Hydrocodone-
Lymphoma
St. Louis UniversityP3CCC (52)
Polatuzumab
Lymphoma
Jennifer Crombie, MDP2CCC (52)
Rifaldazine
Lymphoma
HutchmedP1CCC (52)
Tislelizumab
Lymphoma
Won Seog KimP2CCC (52)
Zilovertamab
Lymphoma
Oncternal Therapeutics, IncP3CCC (52)
Allogeneic Human Umbilical Cord Blood
Lymphoma
Leland MethenyP2CCC (51)
cd19-ucart
Lymphoma
University Hospital TuebingenP1/2CCC (51)
Human Immunoglobulins
Lymphoma
Center for International Blood and Marrow Transplant ResearchP2CCC (51)
Jcar-017 Cd19-Specific Chimeric Antigen Receptor
Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyP2CCC (51)
Lactobacillus Plantarum Strain 299V
Lymphoma
Children's Oncology GroupP3CCC (51)
Taselisib
Lymphoma
National Cancer Institute (NCI)P2CCC (51)
Alectinib
Lymphoma
Cancer Research UKP2/3CCC (50)
Lorazepam
Lymphoma
Center for International Blood and Marrow Transplant ResearchP2CCC (50)
shr2554
Lymphoma
Jiangsu HengRui Medicine Co., Ltd.P1/2CCC (49)
[18F]F-RESCA-R8B4
Lymphoma
RenJi HospitalP2CCC (48)
[18F]F-RESCA-RCCB6
Lymphoma
RenJi HospitalP2CCC (48)
Showing 101 to 150 of 288 assets
PreviousPage 3 of 6Next